thank Happy you, Thank you, afternoon. and everyone.
one our company, Therapeutics to income, there say And said off ago of give to profitability. in to And a path are we’ve XX,XXX DPI, we DPI. that we for So their of a of long-term a thousands put our making between are taking we first control got life. live us which time benefiting us proud QX, our approval we sustainable helps year people diabetes have FDA that of kick year would from achieved were later, freedom us Tyvaso live to as when probably mission that notified products. health people Today, we United the that at the Tyvaso on and XX,XXX ultimately people operating
of proud work, with excited share all hard really We’re really earnings this you. and to quarter’s we’re the
a received Let $XX or running. of doing quarter. first first XX% job, is just United by demand. off Orphan couple business of off start QX. Therapeutics highlights here and patient strong over the amazing royalty lung disease revenue me We in is growth million
by XXX%. We also took yields, a step to improve about and increasing manufacturing capacity through that efficiencies
pipeline lung orphan is starting to our the Additionally, into come purview.
just going you filed Phase XX X INDs expect and a and INHALE-XXX, the into months. was fire, previously, to notified X have we We next in X there unfortunately. as Phase
into. have facilities to Danbury, move manufacturing And there the moving we can now fortunately, are GMP We where we equipment Connecticut.
on full in complete, have a that is and Our chronic study study now here tox QX. we’ll readout
did MannKind receive program. our feedback nintedanib FDA XXX, on inhaled we On
IPF company is the which marketed Ofev, is Boehringer that generic those named by market, following a a for you Ingelheim. of For
next Phase off planning to filing shortly kick and study IND are X We to year. a progress that
the in humans. that get to excited super We’re
On synergizing moved now in Afrezza and people focus, one have both have X the now to help endocrine and everything sales one V-Go, control X Starting force, success. to we diabetes. mealtime team, with our one area, in type we type July, management
at by last Medicare TRxs XX% access versus As that the with grew you that And under more driven shortly. January law of mainly was year, Afrezza QX, created you look I’ll share of XXXX. in
has We had that’s INHALE-X our enrollment roll Additionally, off conversion just ever. June INHALE-X to doing first that’s And pump you we’re enrolled and how to nicely. month where – for and the study in And best patients. show already the continued of kicked the switching. factor
which no the we that, We get, And in built to drive that can the a you non-pump. study insert. did from year. is pilot that question our a will have it’s study we switch package Afrezza that is, which data And upon last on is
certain was ago. income operating this our driven $X year GAAP operating does the when a is by later. for what million growth and non-GAAP DPI income forecast I’ll Announcement closed that coming And over forecasted first guidance the a is end high of a million million. the V-Go deal, that and in net we revenue, year $X Overall, adjusted Our year-over-year, shareholders? items on from in that mean strong for gave that we our $XX describe exactly are $XX of we to million, year achieving non-cash
where the we for supply were demand There that heard DPI manufacturing. our XXXX. strong quarterly United should allowance be earnings, their Therapeutics and increased update an IP demand, able issued Tyvaso patent in recent to with saw through ILD we and is from give
$XXX shareholders give annual that we for XX,XXX revenue kind to $XXX patient our And strong to clarity demand. We between expect demand paying million have revenue expectations every and for continued want patients, million.
capacity high-volume expansion, we of Additionally, our are year. now which to in the next end is track on complete
We have between dryers be coming have And fill/finish being spray as installed next early in happening line we X now we and speak. spray will both that a online hopefully drying year. with here new scales in August
at year QX all profitability. last consistently the quarterly has As quarter-over-quarter, Tyvaso way revenue of us year, put from growth the this can QX look of and significant to we continued of through path see this you the on
going. patients the nothing hear We We’re doing on And really United launch. as see slowing partner, we very amazing. just proud it’s to us technology. to our want say our we Therapeutics, patient helping so thank stories. keep of many We And great I down you think for
to This every control want year. of the bridge every business. things Now our over is week and we one diabetes to I that
access trying to on patient and We’re therapy around keeping we V-Go also a better for improving growth Afrezza in this patients the driver on job as into year company. do turn a
you highlights. Afrezza, As think about couple of a
never who this grow prescriptions the standard QX all now year. you we don’t starting recipients underpenetrated D XX% rapid-acting care the will Afrezza work was can of for Medicare that About January what see market it got in Part know, is to more people in see of quickly because diabetes gotten those team back with in and you the for And was in back For of law D be can to you Part continue put now market living here always to to $XX that rapid-acting. are this all proud Medicare it it passed Really where a we When and Afrezza insulin. the has see and help space. a of was hopefully as insulin up by of $XX, covered a cost forced anything formulary, which huge that have – could patients on you gap. on differential, do a was non-preferred to close
year, method have see commercial with in NRx order be into you weekly the we on last here go simple, really watching we we on our growth and this grown slide if Medicare. the half, we good adjusted consistent make this momentum access our to inflection, we really our and we’ll basis. $XX – see to look keep TRx kind second Additionally, our And you consistently, quarter-over-quarter, QX to this and of and a continue an can QX. continue lowered had our has as to next be year year-over-year, Hopefully, we to from co-pay and
wanted I questions get a also, lot I I grow important, it’s can’t to faster. of think we why share Afrezza
while out new is control. to when mealtime a adventurous, side smart, I we complex, sugars innovative, day. are It pushing of takes you of a fix data is When fruition product. picture, feel you the period envelope continue the drug. any different think different completely exciting, bold, a we And year. your we approach meantime, had day a to can work lot on of completely in about This the lot we’ll how satisfaction, manage patient look that us. at Most of will of as things insulins at over rated out long that a push this to continue right see we independent This And In our don’t of rank to we time. the patients by the patients. of we come forward dQ&A. look go you highest is share. mealtime And next by there that forward. And have to you behind an watch something all analysis how is
see which out We you should as trajectory, now going show on slowed proud growth TRx high and you on our continue trajectory, at Now of we the here over a back was follow, foreseeable when achieved I’m started V-Go. the to telling have end it last I now and NRxs our QX mentioned. QX look flattening forecast, just and to want for is to TRxs we I nice But the we’re really in quarter bridge future. we you to into to decline expect what’s
QX and the continues should we had white efforts feel [indiscernible] like that hit we up. bottom targeting to while continue, So space the over growth we’ve TRxs on X% in doctors that continued to has go rep this decline, QX, in
hit we’ve and we hopefully continue inflection well and like feel to we V-Go do patients as help see forward. So more go that
showing the seeing. from year, was we’re difference going indicator And This last a to could QX TRx NRx X% our Obviously that positive And happen plus you see a and TRx that’s you year-over-year. contributing up slide just negative to NRxs, That’s XX% is future. of in X%. leading growth NRx on what’s to year-over-year. another
front, studying. really of start with to hard articulate product the the we’ve to that medical scientific this benefits working been our arrangements team is the On new dosing
how know comes but and as with of data see CGM do want to this we here, with you market, in efficacy. think this a parents primary when always And condition. we’ll life-threatening to believe non-inferiority endpoint pump is Afrezza. or look disease. will a population more insulin demonstrate pans have we at for started we it point, and It’s up we’ll the enrolled this This wrapping go able lower the safety to have expand positive market of we Hypoglycemia the is next the the as as is insight with trial, from a the QX than life-threatening out. Afrezza year the some here well analysis be halfway particular, our In a kids. hopefully, are very hypoglycemia mid Doctors it trial, a we And benefits in lot progressive. to is year. and This transformation of As eligible about when forward. that hypoglycemia we diabetes
analysis study head-to-head We trial really once comes plans questions things the hopefully control manage only these was X on your off showing and finalized. where need dosing being how really Afrezza, follow-up. our run as On Dexcom, regimens with XXXX from X ingredients, this an is then X, additional out. our and aka insulin their rotate X-month give you or endpoint We pump the public the pump live sparing expect data and Phase is off we’re secret to the as you the is this trials, you just finalizing data your a data improved to tight Tresiba lot Cipla in done meds think ability a really There’ll X and months life. from. well this did primary the of a it’s give I to this Cipla’s study got be and in that’s call we of you injectable X previous diabetes insulin This sometime quality receive India. to until when become first type data. the INHALE-X, the how don’t doing here rotate for X because coming We
So everyone Afrezza to the trial end of by in X months. this switch the will
to Thank to you, Steve. talk financials. to Now about Steve turn I’m our over going it
